Us Anticoagulation Therapy Market Worth Usd 27.83 Billion By 2022 : High Level Of Medication Adherence Associated With Clinics

By Author: Rama Sharma
Total Articles: 137
Comment this article

The market is segmented into products (anticoagulation drugs and PT/INR testing devices) and anticoagulation clinics. The growth in the anticoagulation drugs market is primarily driven by the rising incidence of venous thromboembolism, atrial fibrillation, and stroke; long-term administration and high volume of recurring sales of anticoagulation drugs; and increasing demand for novel oral anticoagulants (NOACs). On the other hand, the high cost of NOACs and requirement of significant investments in the development of anticoagulation drugs are the major factors restraining the growth of this market.

According to a new market research report “US Anticoagulation Therapy Market by Product ((Anticoagulants Drugs (NOACs, Warfarin)), PT/INR Devices (In-Office, Home Testing)), Service Type (Testing & Consulting), Type of Clinic (Hospital Associated, Independent & Pharmacy-based) – Forecast to 2022“, published by MarketsandMarkets™, the market has witnessed a healthy growth rate during the last decade and is expected to grow at a CAGR of 8.5% between 2017 and 2022 to reach USD 27.83 Billion by 2022.

Browse ...
... in-depth TOC on “US Anticoagulation Therapy Market“

29 Tables
25 Figures
86 Pages

Download PDF Brochure: http://www.marketsandmarkets.com/pdfdownload.asp?id=114158575

Factors such as the rising incidence of venous thromboembolism, atrial fibrillation, and stroke; long-term administration and high volume of recurring sales of anticoagulation drugs; and increasing demand for novel oral anticoagulants (NOACs) is driving the growth of this market.

The NOACs segment accounted for the largest share of the US Anticoagulation Therapy Market for drugs in 2016

The US anticoagulation drugs market is categorized into NOACs, warfarin (VKA), and other drugs. In 2016, the NOACs segment accounted for the largest share of the market. Due to the better safety and efficacy of NOACs as compared to traditional therapies, the adoption of NOACs is higher as compared to traditional drugs. In addition, key market players such as Portola Pharmaceuticals (received the FDA approval for its NOAC Betrixaban in July 2017) are focusing on the development of NOACs in order to capitalize on the growth opportunities presented by this shift in market dynamics. Consequently, many other companies are also expected to focus on developing more safe and efficient NOACs in the coming years; this will ensure the continued growth of this segment.

The in-office testing devices accounted for the largest share of the US Anticoagulation Therapy Market for PT/INR testing devices in 2016

The global US Anticoagulation Therapy Market for PT/INR testing devices is segmented into in-office testing devices and home testing devices. In 2016, the in-office testing devices segment dominated the US Anticoagulation Therapy Market for PT/INR testing devices. The large share of this segment is mainly attributed to the large number of patients opting for in-office testing services. However, the home testing devices segment is expected to grow at the highest CAGR due to its advantages such as convenience, time & cost savings, and quick result generation. Additionally, the cost of test devices and the tests themselves are often reimbursable.

By type of service, the testing services held the largest market share of the anticoagulation therapy market for clinics in 2016

On the basis of types of services provided, the US Anticoagulation Therapy Market for clinics is categorized into testing services and consulting services. In 2016, the testing services segment accounted for the largest share of the US Anticoagulation Therapy Market for clinics. The recurring need for PT/INR monitoring is the key factor driving the growth of this market. However, the shift of patients toward novel anticoagulant agents and high adoption of home testing devices are expected to restrain the growth of this market to a certain extent

By type of clinics, hospital associated clinics held the largest market share of the anticoagulation therapy market for clinics in 2016

On the basis of type of clinics, the US Anticoagulation Therapy Market for clinics is categorized into hospital associated clinics, independent clinics, and pharmacy-based clinics. In 2016, the hospital associated clinics segment accounted for the largest share of the US Anticoagulation Therapy Market for clinics.

Request for sample pages @ https://www.marketsandmarkets.com/requestsampleNew.asp?id=114158575

C. H. Boehringer Sohn (Germany), Bristol-Myers Squibb (US), Johnson & Johnson (US), Pfizer (US), Daiichi Sankyo (Japan), and Portola Pharmaceuticals (US) are the major market players in the US Anticoagulation Therapy Market for drugs while Roche (Switzerland), Abbott (US), Siemens (Germany), Alere (US), and CoaguSense (US) are the major market players in the US Anticoagulation Therapy Market for PT/INR home testing devices.

Browse Related Reports

Coagulation/Hemostasis Analyzer Market by Product (Clinical Laboratory & PoCT Analyzers), Consumables, Test (PT, Fibrinogen, APTT, ACT, D Dimer, Platelet Function), Technology (Mechanical, Optical, Electrochemical), End User (PoCT) – Forecast to 2021

http://www.marketsandmarkets.com/Market-Reports/hemostasis-coagulation-analyzer-market-197226392.html

Point-of-Care Diagnostics Market by Products (Glucose, Cardiometabolic Monitoring, & Infectious Disease Testing Kits, Cardiac & Tumor Markers), End Users (Home, Hospitals, Ambulatory Care), Over-the- Counter & Prescription Based – Global Forecast to 2021

http://www.marketsandmarkets.com/Market-Reports/point-of-care-diagnostic-market-106829185.html

About MarketsandMarkets™

MarketsandMarkets™ provides quantified B2B research on 30,000 high growth niche opportunities/threats which will impact 70% to 80% of worldwide companies’ revenues. Currently servicing 5000 customers worldwide including 80% of global Fortune 1000 companies as clients. Almost 75,000 top officers across eight industries worldwide approach MarketsandMarkets™ for their painpoints around revenues decisions.

Our 850 fulltime analyst and SMEs at MarketsandMarkets™ are tracking global high growth markets following the “Growth Engagement Model – GEM”. The GEM aims at proactive collaboration with the clients to identify new opportunities, identify most important customers, write “Attack, avoid and defend” strategies, identify sources of incremental revenues for both the company and its competitors. MarketsandMarkets™ now coming up with 1,500 MicroQuadrants (Positioning top players across leaders, emerging companies, innovators, strategic players) annually in high growth emerging segments. MarketsandMarkets™ is determined to benefit more than 10,000 companies this year for their revenue planning and help them take their innovations/disruptions early to the market by providing them research ahead of the curve.

MarketsandMarkets’s flagship competitive intelligence and market research platform, “RT” connects over 200,000 markets and entire value chains for deeper understanding of the unmet insights along with market sizing and forecasts of niche markets.

Contact:
Mr. Rohan
MarketsandMarkets™ INC.
630 Dundee Road
Suite 430
Northbrook, IL 60062
USA: +1-888-600-6441
Email: sales@marketsandmarkets.com